SEC Tracker
Get the app

Equillium EQ

Equillium FY 2023: revenue $36.1M, up 129%; diluted EPS −$0.38

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Equillium reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$36.1M+129% from $15.8M in FY 202210-K income statement, on EDGAR
  2. Net income−$13.3MAgainst −$62.4M in FY 202210-K income statement, on EDGAR
  3. Diluted EPS−$0.38Against −$1.85 in FY 202210-K income statement, on EDGAR
  4. Cash and cash equivalents$23.2M−61% from $59.1M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  5. Cash from operations−$21.8MAgainst −$8.7M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Equillium files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Zeo ScientifiX ZEOX public float $7M, Apr 30, 2025, over 18 months old
  2. Sunshine Biopharma SBFM public float $7M, Jun 30, 2025
  3. Neuphoria Therapeutics NEUP public float $7M, Dec 31, 2025
  4. CV Sciences CVSI public float $7M, Jun 30, 2025
  5. Minerva Neurosciences NERV public float $7M, Jun 30, 2025